Michael B. Jordan, MD

Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Chandrakasan, S; Jordan, MB; Baker, A; Behrens, EM; Bhatla, D; Chien, M; Eckstein, OS; Henry, MM; Hermiston, ML; Hinson, AP; Walkovich, KJ; Yee, JD; Zoref-Lorenz, A; Allen, CE. Blood Advances. 2024; 8:2248-2258.

COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report. McDonnell, J; Cousins, K; Younger, ME M; Lane, A; Abolhassani, H; Abraham, RS; Al-Tamemi, S; Aldave-Becerra, JC; Al-Faris, EH; Alfaro-Murillo, A; Lim, XR; Lopes, JP; López, AL; Tarquini, L. Journal of Clinical Immunology. 2024; 44:86.

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders. Cournoyer, E; Ferrell, J; Sharp, S; Ray, A; Jordan, M; Dandoy, C; Grimley, M; Roy, S; Lorsbach, R; Merrow, AC; Nelson, A; Bartlett, A; Picarsic, J; Kumar, A. Haematologica: the hematology journal. 2024; 109:1137-1148.

Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation. Böhm, S; Wustrau, K; Pachlopnik Schmid, J; Prader, S; Ahlmann, M; Yacobovich, J; Beier, R; Speckmann, C; Behnisch, W; Ifversen, M; Lindemans, C; Henter, JI; Lehmberg, K; Ehl, S. Blood. 2024; 143:872-881.

Hemophagocytic lymphohistiocytosis: A disorder of T cell activation, immune regulation, and distinctive immunopathology. Jordan, MB. Immunological Reviews. 2024; 322:339-350.

Exposure-safety relationship for patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Jordan, MB; Locatelli, F. Pediatric Blood and Cancer. 2024; 71:e30778.

Here be dragons: A universal profile of recent T-cell (hyper)activation?. Jordan, MB. Journal of Allergy and Clinical Immunology. 2024; 153:98-99.

Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis. Verkamp, B; Zoref-Lorenz, A; Francisco, B; Kieser, P; Mack, J; Blackledge, T; Simon, DB; Yacobovich, J; Jordan, MB. Blood Advances. 2023; 7:7258-7269.

Inpatient recognition and management of HLH. Zoref-Lorenz, A; Ellis, M; Jordan, MB. Hematology-American Society of Hematology Education Program. 2023; 2023:259-266.

Real-World Treatment Patterns and Outcomes Among Patients with Secondary Hemophagocytic Lymphohistiocytosis Treated with Emapalumab in the United States: The Real-HLH Study. Allen, CE; Chandrakasan, S; Jordan, MB; Leiding, JW; Oladapo, A; Pednekar, P; Walkovich, K; Yee, J. Blood. 2023; 142:3909.